Hera Women's Health Highlights Sera Prognostics PRIME Trial Results Led by Brian K. Iriye, MD Showing Biomarker-Guided Care Improves Newborn Outcomes and Reduces NICU Use

Hera Women's Health is highlighting results from the PRIME multicenter randomized controlled trial sponsored by Sera Prognostics, Inc., with Brian K. Iriye, MD (Hera Women's Health) serving as the ...
The New England Journal of Medicine

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...
Lupus Foundation of America

Phase 2b JASMINE trial of nipocalimab demonstrates positive results for treatment of systemic lupus erythematosus

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...